Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01041716 · ClinicalTrials.gov registry record
Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
A clinical trial of Drug Resistance, Microbial, sponsored by Maimonides Medical Center.
- Completed
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT01041716 is a study of Drug Resistance, Microbial that has completed, run by Maimonides Medical Center. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01041716, a study of Drug Resistance, Microbial, has completed, sponsored by Maimonides Medical Center.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Carbapenems are a class of antibiotic agents which kill a broad spectrum of bacteria. Infections due to gram-negative bacteria which have acquired resistance to carbapenems are increasing, especially with Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa . The optimal treatment of such infections is not known. Antibiotics like polymyxin, tigecycline and rifampin are used alone or in combination with other antibiotics. The outcome of using these new and old drugs is not well studied. This observational study aims to study the clinical and microbiological outcomes of these infections and treatment at our institution.
Conditions Studied
Interventions
- OTHER None - Observational study
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01041716
The ClinicalTrials.gov registry entry for NCT01041716 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Resistance, Microbial appearing as the primary indexed condition, and to 1 intervention - of which None - Observational study is the first listed.
NCT01041716 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01041716 about?
NCT01041716 is a clinical study titled "Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria". Carbapenems are a class of antibiotic agents which kill a broad spectrum of bacteria. Infections due to gram-negative bacteria which have acquired resistance to carbapenems are increasing, especially with Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa . The optimal treatme...
What is the current status of trial NCT01041716?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2009-12. Estimated completion is 2010-12.
What conditions does trial NCT01041716 study?
This clinical trial studies the following conditions: Drug Resistance, Microbial.
What interventions are being tested in trial NCT01041716?
The interventions under investigation include: None - Observational study (OTHER).
Who is sponsoring clinical trial NCT01041716?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01041716 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.